{"count": 1, "results": [{"_id": "31698459", "pmid": 31698459, "title": "Association between clinical outcomes and metformin use in adults with sickle cell disease and diabetes mellitus.", "journal": "Blood Adv", "authors": ["Badawy SM", "Payne AB"], "date": "2019-11-12T00:00:00Z", "doi": "10.1182/bloodadvances.2019000838", "meta_date_publication": "2019 Nov 12", "meta_volume": "3", "meta_issue": "21", "meta_pages": "3297-3306", "score": 50062.625, "text_hl": "Of 457 adults (median age [interquartile range], 43 years [33-52 years]; 72% female), 142 (31%) were treated with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@. Adjusted for age, sex, and Charlson Comorbidity Index, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ users had significantly lower rate ratios of all-cause inpatient encounters (0.68; 95% confidence interval [CI], 0.52-0.88; P < .01), inpatient encounters with @DISEASE_Anemia_Sickle_Cell @DISEASE_MESH:D000755 @@@SCD@@@ codes (0.45; 95% CI, 0.30-0.66; P < .01), ED encounters with @DISEASE_Anemia_Sickle_Cell @DISEASE_MESH:D000755 @@@SCD@@@ codes (0.34; 95% CI, 0.21-0.54; P < .01), VOE (0.22; 95% CI, 0.12-0.41; P < .01), @<m>DISEASE_Acute_Chest_Syndrome</m> @DISEASE_MESH:D056586 @@@ACS@@@ (0.17; 95% CI, 0.05-0.60; P = .01), and @DISEASE_Osteonecrosis @DISEASE_MESH:D010020 @@@AVN@@@ (0.30; 95% CI, 0.11-0.87; P = .03). ", "citations": {"NLM": "Badawy SM, Payne AB. Association between clinical outcomes and metformin use in adults with sickle cell disease and diabetes mellitus. Blood Adv. 2019 Nov 12;3(21):3297-3306. PMID: 31698459", "BibTeX": "@article{31698459, title={Association between clinical outcomes and metformin use in adults with sickle cell disease and diabetes mellitus.}, author={Badawy SM and Payne AB}, journal={Blood Adv}, volume={3}, number={21}, pages={3297-3306}}"}}]}